Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses

Fig. 2

Patients harboring Class 3 BRAF mutations show better prognosis than those with Class 1/2 mutations analyzed in a public cBioPortal cohort. Percentages of patients with (A) RAS-active alterations and (B) MSI-H are shown by BRAF subgroups. (C) The distribution of TMB. (D-E) Kaplan-Meier analyses of progression-free survival and overall survival for patients with different classes of BRAF mutations 

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us